Prescient Therapeutics (ASX:PTX) received notices of allowance from the USPTO for two new patents covering its PTX-200 drug for treating leukemia and breast cancer.
After receiving the grant, patents are anticipated to be valid until at least 2025.
The PTX-200 patents (USPTO 15/487,854 and 15/487,843) are valuable additions to strong IP portfolio of PTX and will further augment protection of PTX-200.
Post announcement on 17 June 2020, PTX shares surged up by 7.3% to A$0.059 (at AEST 12:02 PM).
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.